Joel Schlessinger M.D.

Dr. Joel Schlessinger and his staff recently performed clinical trials for a new Botox alternative from Johnson & Johnson. If approved in the U.S. next year, this new anti-wrinkle drug could become a significant competitor of Botox.

This new anti-wrinkle drug could become a staple in cosmetic procedures. Dr. Joel Schlessinger explains. 

Johnson & Johnson hopes this treatment remains comparable to Botox in safety and effectiveness. But once this unnamed injectable is approved for use in the United States, it could become as popular as its counterpart.

Introduced to the U.S. over a decade ago, Botox is used to temporarily smooth fine lines and wrinkles on the face. It has also been approved to prevent excessive sweating, migraines and overactive bladder. Experts say if marketed properly at a lower price point, Johnson & Johnson’s new drug will become an excellent alternative to Botox.

Dr. Joel Schlessinger is excited to offer this new injectable to his patients once it is approved for use in the U.S.

“I am looking forward to its availability,” he said. “I am delighted we could be a part of the clinical trials.”

As an expert in the fields of dermatology and cosmetic surgery, Dr. Joel Schlessinger participates in several innovative studies each year.

Dr. Joel Schlessinger frequently participates in studies centered on new drug and treatment options. Some of these studies include:

• Dr. Joel Schlessinger’s study on double chins to be released soon
• Dr. Joel Schlessinger administers study on the treatment of Hidradenitis Suppurativa
• Dr. Joel Schlessinger studies the treatment of acne vulgaris with adapalene 0.1% lotion
• Dr. Joel Schlessinger reviews study of a treatment of actinic keratosis

Are you interested in participating in a local research study with Dr. Joel Schlessinger? If you live in the Omaha area, visit our website for more information on our current studies.